Followers | 375 |
Posts | 16969 |
Boards Moderated | 4 |
Alias Born | 03/07/2014 |
Thursday, April 03, 2014 7:25:36 PM
http://stemcellceo.com/wp/bioheart/404/
" Most recently we concluded enrollment and treatment of the patients in the Phase I Angel trial for LipiCell™. Patients with chronic heart ischemia received transplantation of LipiCell™ through endocardia implantations with an injection catheter." (CEO speaking)
So it is said they were treated with a product specifically named "Lipicell".
Now you read this SEC document: 10-Q, PAGE 29, Sept 30, 2013 and it seems confusing, as it indicated that "Adipocell" is a "different" product "licensed" from a different source?
http://www.sec.gov/Archives/edgar/data/1388319/000114544313002166/d30730.htm
PAGE 29:
"AdipoCell
Bioheart has successfully completed various trials using adipose stem cells. In August 2013, the Company canceled its license agreement with the Ageless Regenerative Institute for adipose derived stem cells called LipiCell. Bioheart has entered into a term sheet agreement with Invitrx to License their adipose derived stem cell products. Bioheart has changed its adipose derived stem cell product name to AdipoCell. "
Just confusing IMHO? If you treated people with a product from Ageless, as in a very specific product/process called "Lipocell" and then you "licensed" something apparently "different" from Invitrix and named it "Adipocell"- then how did the people treated with Lipocell per the CEO PR above, now get labeled as having received "Adipocell"- something "licensed" from a different source?
Unless the two products/processes are IDENTICAL to the tee- I don't see how you can interchange them freely in PR, having said the group originally received "Lipicell" (that's what CEO says above), but now the PR says they received something called "Adipocell"?
Again, just very confusing to me IMO only. That's just me. It seems like two different products- since it involves licensing from "Invitrex"- so I don't know how "on the fly" you can just change a name- but say the "treatment" they received was now for "Adipocell" - when it's clear in former communications, that it's stated with 100% clarity IMHO, that they were actually injected with "Lipicell"? Oh well, maybe I'm not smart enough to follow it- or understand all the changes and changes to PR as they go along? Who knows?
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM